← Leaderboards
Chang Liu
Newventureiq, Llc
$787,796
Attributed
$1,291,309
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $467.5K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,291,309 · 4
By mechanism
R43$575,777 · 2
R21$431,250 · 1
R41$284,282 · 1
Top collaborators
- Brian Todd Edelson2 shared
- Hongjie Guo2 shared
Others in their field
Other Emerging Leaders on “Antigens”
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$42,191,190
- Bala Raja · Luminostics, Inc.$28,624,460
- Hanjoon Ryu$28,519,898
- Thomas Denny · Duke University$22,999,550
- Jay Evans · University Of Montana$22,565,626
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
AntigensHla AntigensHybridomasChimeric ProteinsEngineeringLifeProteinsIn VitroBiological ProductsAntibodiesPrototypeImmunogenicityInfection ControlImmunosuppressionTherapeutic TargetAntibody-Producing CellsImmune ResponseImmunoglobulin-Secreting CellsInfection RiskB-LymphocytesHaplotypesHistocompatibility Antigens Class IHumoral ImmunitiesDonor-Specific Antibody
Grant awards (5)
Peptide-HLA-DQ8 biologics for antigen-specific therapy in Type 1 Diabetes$303,274
R43 · FY2025 · AI
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.$272,503
R43 · FY2023 · AI
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins$195,000
R21 · FY2023 · AI
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins$236,250
R21 · FY2022 · AI
Rapid high-resolution typing of Human Leukocyte Antigen genes by nanopore sequencing for transplantation$284,282
R41 · FY2019 · AI · contact PI